JP2019150066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019150066A5 JP2019150066A5 JP2019113625A JP2019113625A JP2019150066A5 JP 2019150066 A5 JP2019150066 A5 JP 2019150066A5 JP 2019113625 A JP2019113625 A JP 2019113625A JP 2019113625 A JP2019113625 A JP 2019113625A JP 2019150066 A5 JP2019150066 A5 JP 2019150066A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- acid sequence
- domain
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020199336A JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514875.2 | 2015-08-20 | ||
| GBGB1514875.2A GB201514875D0 (en) | 2015-08-20 | 2015-08-20 | Receptor |
| JP2018509549A JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Division JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199336A Division JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019150066A JP2019150066A (ja) | 2019-09-12 |
| JP2019150066A5 true JP2019150066A5 (enExample) | 2021-01-21 |
| JP6979423B2 JP6979423B2 (ja) | 2021-12-15 |
Family
ID=54292003
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10800854B2 (enExample) |
| EP (3) | EP3337814A1 (enExample) |
| JP (6) | JP2018523485A (enExample) |
| KR (2) | KR102669749B1 (enExample) |
| CN (2) | CN110724200B (enExample) |
| AU (1) | AU2016308618B2 (enExample) |
| BR (1) | BR112018003308A2 (enExample) |
| CA (2) | CA2995785A1 (enExample) |
| CL (2) | CL2018000415A1 (enExample) |
| ES (1) | ES3076016T3 (enExample) |
| GB (1) | GB201514875D0 (enExample) |
| HK (1) | HK1252161A1 (enExample) |
| IL (2) | IL270207B2 (enExample) |
| MX (2) | MX2018002042A (enExample) |
| RU (1) | RU2018109350A (enExample) |
| SG (1) | SG10201909759UA (enExample) |
| WO (1) | WO2017029512A1 (enExample) |
| ZA (1) | ZA201904156B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| US11654158B2 (en) | 2016-11-17 | 2023-05-23 | 2Seventy Bio, Inc. | TGFBeta signal convertor |
| CA3045667A1 (en) * | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP2020532987A (ja) * | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| GB201714718D0 (en) * | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| CA3084551A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| AU2019227979B2 (en) * | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| SG11202009975TA (en) | 2018-04-12 | 2020-11-27 | Umoja Biopharma Inc | Viral vectors and packaging cell lines |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| CN112469440B (zh) | 2018-06-18 | 2024-09-06 | 优瑞科生物技术公司 | 靶向前列腺特异性膜抗原(psma)的构建体和其用途 |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201812474D0 (en) | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
| WO2020044239A1 (en) * | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| SG11202102781UA (en) | 2018-09-27 | 2021-04-29 | Autolus Ltd | Chimeric antigen receptor |
| US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| IL285941B1 (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| MA55911A (fr) | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Lymphocytes t génétiquement modifiés |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| EP4041299A4 (en) * | 2019-10-10 | 2024-07-31 | Bryologyx Inc. | Method of induction of tumor associated antigens with bryostatin |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| JP7840865B2 (ja) | 2020-03-31 | 2026-04-06 | フレッド ハッチンソン キャンサー センター | キメラ抗原受容体ターゲティングｃｄ３３ |
| EP4126925A4 (en) * | 2020-03-31 | 2024-07-24 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33 |
| EP4132962A1 (en) | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| CN113201063B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途 |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| JP7557042B2 (ja) * | 2020-08-19 | 2024-09-26 | 山東博安生物技術股▲ふん▼有限公司 | ステルスキメラ抗原受容体及び正常細胞への細胞毒性の低減におけるその用途 |
| CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
| CA3217252A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
| CN113072648B (zh) * | 2021-06-04 | 2021-08-24 | 诺未科技（北京）有限公司 | 一种靶向afp的肝癌疫苗 |
| CN113416708A (zh) * | 2021-06-10 | 2021-09-21 | 深圳市先康达生命科学有限公司 | 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用 |
| KR102827437B1 (ko) * | 2021-08-30 | 2025-07-02 | 연세대학교 산학협력단 | 림프종의 예방 또는 치료를 위한 림프종 세포 특이적 약물 전달체 및 이의 제조방법 |
| EP4402161A1 (en) * | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| EP4519294A1 (en) * | 2022-05-04 | 2025-03-12 | Earli Inc. | Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells |
| CA3259305A1 (en) * | 2022-07-11 | 2024-01-18 | Sonoma Biotherapeutics, Inc. | RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE |
| JP2025529913A (ja) * | 2022-08-26 | 2025-09-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラサイトカイン受容体及び使用方法 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| EP4630446A1 (en) * | 2022-12-06 | 2025-10-15 | Dynamic Cell Therapies, Inc. | Engineered switches for immune cell activity and methods of use thereof |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| EP4680748A1 (en) | 2023-03-13 | 2026-01-21 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| AU2024240076A1 (en) | 2023-03-20 | 2025-08-28 | Autolus Limited | A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma |
| WO2024238287A1 (en) * | 2023-05-12 | 2024-11-21 | Chimeris Uk Ltd. | Dual blocking and chimeric cytokine receptor |
| GB202309704D0 (en) | 2023-06-27 | 2023-08-09 | Autolus Ltd | Chimeric transmembrane protein |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
| WO2026149447A1 (zh) * | 2025-01-07 | 2026-07-16 | 深圳市济因生物科技有限公司 | 一种颗粒及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08508889A (ja) | 1993-06-07 | 1996-09-24 | アムジエン・インコーポレーテツド | ハイブリッドレセプター分子 |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| NZ507886A (en) * | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| JP4009535B2 (ja) * | 2001-03-09 | 2007-11-14 | ザイモジェネティクス，インコーポレイティド | 可溶性ヘテロダイマーサイトカイン受容体 |
| CN1659274A (zh) * | 2002-04-19 | 2005-08-24 | 津莫吉尼蒂克斯公司 | 细胞因子受体 |
| JP2004113062A (ja) * | 2002-09-25 | 2004-04-15 | Teruyuki Nagamune | キメラ受容体を有する動物細胞とその利用 |
| CN101027079B (zh) * | 2004-10-12 | 2011-08-17 | 美国蛋白质公司 | 嵌合蛋白 |
| WO2007115230A2 (en) * | 2006-03-30 | 2007-10-11 | University Of Medicine And Dentistry Of New Jersey | A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| EP2389443B1 (en) * | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| WO2011034660A1 (en) | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| RU2522004C2 (ru) | 2012-04-10 | 2014-07-10 | Владимир Константинович Боженко | Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения. |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MA41538A (fr) | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| SG11202102781UA (en) | 2018-09-27 | 2021-04-29 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-08-20 GB GBGB1514875.2A patent/GB201514875D0/en not_active Ceased
-
2016
- 2016-08-19 CN CN201911010436.8A patent/CN110724200B/zh active Active
- 2016-08-19 AU AU2016308618A patent/AU2016308618B2/en active Active
- 2016-08-19 JP JP2018509549A patent/JP2018523485A/ja not_active Withdrawn
- 2016-08-19 HK HK18111554.5A patent/HK1252161A1/zh unknown
- 2016-08-19 WO PCT/GB2016/052564 patent/WO2017029512A1/en not_active Ceased
- 2016-08-19 MX MX2018002042A patent/MX2018002042A/es unknown
- 2016-08-19 KR KR1020187007751A patent/KR102669749B1/ko active Active
- 2016-08-19 CA CA2995785A patent/CA2995785A1/en not_active Abandoned
- 2016-08-19 US US15/753,486 patent/US10800854B2/en active Active
- 2016-08-19 CA CA3091907A patent/CA3091907C/en active Active
- 2016-08-19 BR BR112018003308-1A patent/BR112018003308A2/pt not_active Application Discontinuation
- 2016-08-19 SG SG10201909759U patent/SG10201909759UA/en unknown
- 2016-08-19 ES ES18189793T patent/ES3076016T3/es active Active
- 2016-08-19 MX MX2019013204A patent/MX421045B/es unknown
- 2016-08-19 IL IL270207A patent/IL270207B2/en unknown
- 2016-08-19 RU RU2018109350A patent/RU2018109350A/ru unknown
- 2016-08-19 EP EP16756758.5A patent/EP3337814A1/en active Pending
- 2016-08-19 CN CN201680046834.3A patent/CN108350047A/zh active Pending
- 2016-08-19 EP EP23216609.0A patent/EP4338756A3/en active Pending
- 2016-08-19 EP EP18189793.5A patent/EP3438123B1/en active Active
- 2016-08-19 KR KR1020247017118A patent/KR20240093884A/ko active Pending
-
2018
- 2018-01-30 IL IL257234A patent/IL257234A/en unknown
- 2018-02-15 CL CL2018000415A patent/CL2018000415A1/es unknown
- 2018-08-27 US US16/113,224 patent/US10800855B2/en active Active
-
2019
- 2019-04-23 CL CL2019001107A patent/CL2019001107A1/es unknown
- 2019-06-19 JP JP2019113625A patent/JP6979423B2/ja active Active
- 2019-06-26 ZA ZA2019/04156A patent/ZA201904156B/en unknown
-
2020
- 2020-08-20 US US16/998,756 patent/US11479613B2/en active Active
- 2020-08-20 US US16/999,012 patent/US11479614B2/en active Active
- 2020-12-01 JP JP2020199336A patent/JP7603426B2/ja active Active
-
2022
- 2022-07-26 US US17/815,110 patent/US12234295B2/en active Active
- 2022-11-07 JP JP2022178045A patent/JP2022190153A/ja not_active Withdrawn
-
2025
- 2025-01-21 US US19/033,252 patent/US20250333538A1/en active Pending
- 2025-03-21 JP JP2025047075A patent/JP2025089404A/ja active Pending
- 2025-03-21 JP JP2025047074A patent/JP2025089403A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021035395A5 (enExample) | ||
| CN110662560B (zh) | 改进的抗原结合受体 | |
| JP2022523961A5 (enExample) | ||
| JP2023091037A (ja) | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| JP2019535262A5 (enExample) | ||
| CN109069537B (zh) | 共刺激结构域中具有重复结合基序的car | |
| JP2022109953A5 (enExample) | ||
| JP2023521663A5 (enExample) | ||
| CN108350462B (zh) | 嵌合抗原受体及其用途 | |
| JP2018523485A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| JP2022531222A5 (enExample) | ||
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| JP2018523484A5 (enExample) | ||
| JP2018526033A5 (enExample) | ||
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| CN114391021A (zh) | TGF-β受体和使用方法 | |
| TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
| CN111479918A (zh) | 细胞 | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| CN116096739A (zh) | 嵌合抗原受体间隔物 | |
| JP2023527613A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| CN112996819B (zh) | 细胞分选系统及使用方法 | |
| WO2023037125A1 (en) | Binding domain | |
| CN115521917A (zh) | 工程化免疫细胞及其用途 |